While undergoing parallel review for its FoundationOne test by the FDA and CMS, the firm will continue to work with its local MACs on reimbursement.
The insurer will cover Metamark's urology specialized diagnostics throughout the state.
The blood-based test will be covered by one of the largest health plans in the state of Michigan.
The deal is the latest coverage and reimbursement success for the Cambridge, Massachusetts-based urology diagnostics firm.
The colon cancer screening test is now covered in-network by the insurance company in Indiana, Ohio, Kentucky, Missouri, and Wisconsin.
The insurer is the latest to provide coverage for NanoString's gene expression-based breast cancer recurrence risk test.
Natera said that a greater proportion of NIPTs for average-risk pregnancies are being reimbursed, while reimbursement for microdeletion testing is declining.
Bank of America, Phoenix Children's Hospital, and Sanford Health said they would cover NantHealth's GPS Cancer test for some cancers.
Aetna considers the test "medically necessary" and the decision opens the door for 19 million people to access the risk classifier test.
Sequenom has secured in-network status with seven state Anthem BCBS plans to provide NIPT to both high- and average-risk pregnancies.
Bioethicists disagree with a research team's decision to allow the return of risk results for adult-onset conditions from a newborn sequencing project, according to Reuters.
Alterations to particular gene may enable the Quechua of Peru to better tolerate high-altitude life, Ars Technica reports.
Nature News reports that additional South Korean researchers have included the names of children on scientific papers when they did not contribute to the work.
In PLOS this week: statistical approach to prioritize rare variant searches, gene expression alterations in chronic obstructive pulmonary disease, and more.